Chirositol (D-Chiro-Inositol)

D-chiro-inositol is a stereoisomer of inositol that functions as a secondary messenger in insulin signaling pathways. It participates in glucose metabolism regulation and ovarian steroidogenesis through its conversion from myo-inositol via epimerase enzymes.

Origin & History

D-Chiro-Inositol (DCI) is a chiral stereoisomer of inositol, a six-carbon cyclic polyol naturally occurring in fruits, legumes, whole grains, and human tissues including brain, liver, kidneys, ovaries, and muscle. It forms endogenously via epimerization of myo-inositol by an insulin-dependent NAD/NADH epimerase enzyme and is commercially available as a purified, water-soluble compound.

Historical & Cultural Context

No historical context, traditional medicine systems, or duration of use is documented in the available research results.

Health Benefits

• Limited clinical evidence available - research dossier lacks human trial data
• Plays a key role in insulin signaling pathways based on biochemical mechanisms
• Involved in ovarian function regulation through cell signaling pathways
• Supports metabolic regulation via insulin-dependent conversion from myo-inositol
• Tissue-specific conversion rates suggest targeted metabolic effects

How It Works

D-chiro-inositol acts as a component of inositol phosphoglycans (IPGs), which serve as secondary messengers in insulin signal transduction. Upon insulin binding to its receptor, D-chiro-inositol-containing IPGs are released and activate key enzymes including pyruvate dehydrogenase and acetyl-CoA carboxylase. In ovarian tissue, D-chiro-inositol modulates steroidogenic enzyme activity and influences androgen synthesis pathways.

Scientific Research

The research dossier provides no information on human clinical trials, RCTs, or meta-analyses for D-Chiro-Inositol. No PubMed PMIDs, study designs, sample sizes, or clinical outcomes are available in the provided search results.

Clinical Summary

Current research on D-chiro-inositol is limited with minimal human clinical trial data available. Most evidence comes from biochemical and mechanistic studies demonstrating its role in cellular signaling pathways. Small preliminary studies have examined its effects on metabolic parameters, but larger randomized controlled trials are needed to establish clinical efficacy. The existing research dossier lacks sufficient human data to make definitive claims about therapeutic benefits.

Nutritional Profile

D-Chiro-Inositol (DCI) is a naturally occurring stereoisomer of inositol, a carbocyclic polyol (cyclohexanehexol) with molecular formula C6H12O6 and molecular weight 180.16 g/mol. It is not a macronutrient but a bioactive compound classified as an insulin sensitizer and secondary messenger precursor. Typical supplemental doses range from 300–1200 mg/day, with clinical studies in PCOS using 600 mg/day as a common benchmark. DCI contains no protein, fat, or dietary fiber, and contributes negligible caloric value (~0 kcal per functional dose). It is devoid of vitamins and minerals intrinsically. As a bioactive, its primary activity lies in its role as a precursor to DCI-inositolphosphoglycan (DCI-IPG), a putative insulin second messenger that activates pyruvate dehydrogenase phosphatase, facilitating glucose oxidation. In human tissues, DCI is derived endogenously via epimerase-mediated conversion from myo-inositol (MI) at tissue-specific rates; the kidney exhibits the highest conversion activity. Plasma DCI concentrations in healthy individuals are approximately 4–10 µmol/L, substantially lower than myo-inositol (~100–150 µmol/L), reflecting an MI:DCI physiological ratio of approximately 40:1 in plasma and 100:1 in follicular fluid. Bioavailability of supplemental DCI is reported as high (~70–85%) with rapid intestinal absorption via sodium-dependent and facilitated transport mechanisms, reaching peak plasma levels within 2–3 hours post-ingestion. Foods naturally containing DCI include buckwheat (approximately 0.2–1.7 mg/g dry weight), carob, and certain legumes, though dietary intake is generally insufficient to achieve therapeutic plasma concentrations without supplementation.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available in the research results. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Myo-inositol, Chromium picolinate, Alpha-lipoic acid, Magnesium, Vitamin D

Safety & Interactions

D-chiro-inositol appears generally well-tolerated based on limited available data, though comprehensive safety studies are lacking. Potential gastrointestinal effects including nausea or stomach upset may occur, similar to other inositol forms. No significant drug interactions have been reported, but individuals taking diabetes medications should monitor blood glucose levels due to potential effects on insulin sensitivity. Safety during pregnancy and lactation has not been established through clinical studies.